3 Factors That Make HUM Poised for Significant Growth

Humana’s Challenging Half-Year: What’s Next?

Humana has endured a difficult six months, with its share price tumbling 41.1% to $175.98. This significant decline, driven in part by weaker-than-expected quarterly results, has left many investors uncertain about their next steps.

With the stock under pressure, some may wonder if this is an attractive entry point for HUM.

Why We Remain Optimistic About Humana

Humana (NYSE:HUM) generates over 80% of its revenue from federal government contracts, serving around 17 million members with a strong emphasis on Medicare Advantage plans for seniors. The company is a major player in the health insurance and healthcare services sector.

1. Consistent Revenue Expansion

Long-term growth is a key measure of a company’s strength. While any business can have a few strong quarters, sustained progress sets the best apart. Over the past five years, Humana has achieved an average annual revenue increase of 11.2%, outpacing many of its healthcare peers and demonstrating strong demand for its offerings.

Humana Quarterly Revenue

2. Scale Provides Competitive Advantages

Larger organizations often benefit from economies of scale, spreading fixed costs like infrastructure and technology across a greater number of customers, which lowers the average cost per service. This scale also enhances bargaining power with suppliers, boosts brand recognition, and increases the ability to invest in growth. When managed well, these advantages can reinforce a company’s market position.

With $129.8 billion in revenue over the past year, Humana stands among the largest healthcare companies. This scale is especially valuable in the insurance industry, where high volumes are essential due to typically slim profit margins.

3. Exceptional Return on Invested Capital (ROIC)

While growth is important, how efficiently a company uses its capital is equally critical. ROIC measures how much operating profit a company generates relative to the capital it has raised through debt and equity.

Humana’s average ROIC over the past five years is an impressive 32.9%, placing it among the top performers in healthcare. This highlights the management team’s ability to allocate resources effectively and deliver strong returns for shareholders.

Our Takeaway

These factors underscore why Humana is considered a high-quality company. Following its recent decline, the stock is now valued at 18.6 times forward earnings, or $175.98 per share. Is this the right moment to invest?

Building a Resilient Portfolio with Quality Stocks

Relying on just a handful of stocks can leave your investments vulnerable. Now is a limited window to secure shares in high-quality companies before market conditions shift and valuations rise.

Discover Top-Performing Stocks

Don’t wait for the next bout of market turbulence. Explore our Top 9 Market-Beating Stocks—a handpicked selection of high-quality companies that have delivered a remarkable 244% return over the past five years (as of June 30, 2025).

This list features well-known names like Nvidia, which soared 1,326% from June 2020 to June 2025, as well as lesser-known success stories such as Kadant, a former micro-cap that achieved a 351% five-year return. Start your search for the next standout investment with StockStory today.